News provided by CVS Health May 28, 2026, 06:45 ET Expanded GLP-1 options for members create a path to sustainable coverage of these important medications WOONSOCKET, R.I., May 28, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members including the reintroduction of Zepbound (tirzepatide) as a covered medication
Atopic Dermatitis or Eczema PictureEczema is a skin condition caused by inflammation
Revive Rx Pharmacy Mixes up Labels for Diabetes Medication In April of 2024, it was discovered that Revive Rx, a compounding pharmacy in Texas, had mislabeled their 10-milligram sterile solution of Tirzepatide vials and their 2-milliliter multidose vials
T2D, notorious for its macrovascular and microvascular complications, presents a heavy challenge for health care systems [3]
Manufacturers may offer savings cards or copay programs
Nephrol Dial Transplant 21: 3211-3214 Rizos I (2000) Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration